BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 952 filers reported holding BAXTER INTL INC in Q1 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $177,733,000 | +17.0% | 3,427,272 | +0.1% | 0.14% | +13.3% |
| Q4 2016 | $151,869,000 | +43.6% | 3,424,905 | +54.1% | 0.13% | +43.8% |
| Q3 2016 | $105,773,000 | +93.3% | 2,222,127 | +83.6% | 0.09% | +93.5% |
| Q2 2016 | $54,717,000 | -57.2% | 1,210,041 | -61.1% | 0.05% | -58.6% |
| Q1 2016 | $127,705,000 | -8.4% | 3,108,608 | -14.9% | 0.11% | -6.7% |
| Q4 2015 | $139,357,000 | -50.9% | 3,652,872 | -57.7% | 0.12% | -7.0% |
| Q3 2015 | $283,902,000 | +75.0% | 8,642,346 | +272.6% | 0.13% | -3.8% |
| Q2 2015 | $162,187,000 | +16.8% | 2,319,274 | +14.4% | 0.13% | +16.7% |
| Q1 2015 | $138,898,000 | +93.9% | 2,027,714 | +107.5% | 0.11% | +86.9% |
| Q4 2014 | $71,634,000 | -0.3% | 977,405 | -2.3% | 0.06% | -7.6% |
| Q3 2014 | $71,835,000 | -3.5% | 1,000,905 | -2.8% | 0.07% | -2.9% |
| Q2 2014 | $74,440,000 | -14.5% | 1,029,605 | -13.0% | 0.07% | -16.0% |
| Q1 2014 | $87,082,000 | -62.7% | 1,183,505 | -64.8% | 0.08% | -63.2% |
| Q4 2013 | $233,667,000 | -4.5% | 3,359,695 | -9.8% | 0.22% | -9.5% |
| Q3 2013 | $244,591,000 | -20.3% | 3,723,419 | -16.0% | 0.24% | -24.1% |
| Q2 2013 | $307,021,000 | – | 4,432,229 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |